News – Page 1035 – Endpoints News

Bayer scrutinizes R&D group's productivity as staffers fear layoffs in wake of a revamp

8 years ago

Celgene CEO Mark Alles poaches a top J&J exec for his senior crew during a C-suite makeover

8 years ago

J&J racks up a fresh set of positive pivotal data for depression drug esketamine — but questions linger on safety

8 years ago

Dova picked up its newly approved drug castoff for a song — but payers will be singing the blues about the price

8 years ago

Ironwood dodges a Denner board seat, but the activist investor still has words of advice

8 years ago

Astellas, FibroGen hit primary endpoint in PhIII; vTv inks PDE4 inhibitor deal with Newsoara

8 years ago

ScPharma's stock droops on 'deficiencies' as FDA tosses back heart failure drug application

8 years ago

Bay Area startup Cortexyme gains a $76M round to back a PhII Alzheimer's study, with a new target in their sights

8 years ago

Novartis loses a head honcho, with US oncology head Bill Hinshaw exiting for new gig at Axcella

8 years ago

Madrigal shares soar on promising PhII NASH data, stoking hopes for a new contender

8 years ago

Gilead and Galapagos bag promising PhII data for star immunology drug filgotinib — boosting late-stage focus

8 years ago

Following ASCO preview flop, Syndax bets on new combo deal with Nektar

8 years ago

FDA slaps a clinical hold on sickle cell IND filed for a new gene therapy from Vertex and CRISPR Therapeutics

8 years ago

After tracking success in animals, neurosciences star Denali moves early to bag an option on a promising tech for ...

8 years ago

Trump signs right-to-try bill, says 'massive' voluntary drug price cuts coming in two weeks

8 years ago

Sanofi fires back at Roseanne: 'racism is not a side effect' of Ambien

8 years ago

Zai Lab licenses psoriasis drug from Crescendo; HitGen, Lion raise cash for discovery and development work in Asia

8 years ago

PhRMA's new report counts each cancer drug in the US pipeline, which has now swelled to over 1,000 in the clinic

8 years ago

J&J hustles Legend’s promising BCMA CAR-T into PhI/II trial, winning an FDA green light to begin recruiting ...

8 years ago

FDA moves Sage’s postpartum depression drug brexanolone into regulators’ busy priority lane

8 years ago

FDA executes a 180 on TherapeuticsMD therapy, handing it an OK — and stoking concerns about political influence

8 years ago

AstraZeneca writes off its second pivotal COPD trial for Fasenra, killing expansion plans

8 years ago

Racing to grab market share in diabetes, Novo touts its oral semaglutide win over Jardiance in PhIIIa trial

8 years ago

Astellas wins priority review for AML drug; Takeda shareholders revolt against $62B Shire deal

8 years ago

First page Previous page 1032 1033 103410351036 1037 1038 Next page Last page